126 related articles for article (PubMed ID: 22747472)
41. In situ expression of mononuclear cell markers and interleukin-2 receptor in renal allograft biopsies of acute rejection and borderline cases.
Rodrigues FM; de Carvalho MF; Franchi MR; Gandin CM; Viero RM
Ren Fail; 2007; 29(1):29-35. PubMed ID: 17365907
[TBL] [Abstract][Full Text] [Related]
42. The extent of peritubular CD14 staining in renal allografts as an independent immunohistological marker for acute rejection.
Dooper IM; Hoitsma AJ; Maass CN; Assmann KJ; Tax WJ; Koene RA; Bogman MJ
Transplantation; 1994 Oct; 58(7):820-7. PubMed ID: 7524205
[TBL] [Abstract][Full Text] [Related]
43. Establishment of a high sensitivity plasma assay for human pentraxin3 as a marker for unstable angina pectoris.
Inoue K; Sugiyama A; Reid PC; Ito Y; Miyauchi K; Mukai S; Sagara M; Miyamoto K; Satoh H; Kohno I; Kurata T; Ota H; Mantovani A; Hamakubo T; Daida H; Kodama T
Arterioscler Thromb Vasc Biol; 2007 Jan; 27(1):161-7. PubMed ID: 17095712
[TBL] [Abstract][Full Text] [Related]
44. The role of pentraxin-3 as a prognostic biomarker in paraquat poisoning.
Yeo CD; Kim JW; Kim YO; Yoon SA; Kim KH; Kim YS
Toxicol Lett; 2012 Jul; 212(2):157-60. PubMed ID: 22210019
[TBL] [Abstract][Full Text] [Related]
45. Plasma and tissue expression of the long pentraxin 3 during normal pregnancy and preeclampsia.
Rovere-Querini P; Antonacci S; Dell'Antonio G; Angeli A; Almirante G; Cin ED; Valsecchi L; Lanzani C; Sabbadini MG; Doglioni C; Manfredi AA; Castiglioni MT
Obstet Gynecol; 2006 Jul; 108(1):148-55. PubMed ID: 16816069
[TBL] [Abstract][Full Text] [Related]
46. Effects of hypoxia-inducible factor-1alpha expression and C4d deposition in implantation biopsies on renal allograft.
Kim DJ; Lee S; Kim SJ; Park SG; Kim JS; Hyun SJ; Song YS; Nam ES
Transplant Proc; 2008 Sep; 40(7):2145-6. PubMed ID: 18790175
[TBL] [Abstract][Full Text] [Related]
47. Associations of plasma pentraxin 3 and monocyte chemoattractant protein-1 concentrations with cardiovascular disease in patients with chronic kidney disease.
Nishi K; Imamura T; Kitamura K; Ogawa T; Fujimoto S; Kakitsubata Y; Ishikawa T; Asada Y; Kodama T
Ren Fail; 2011; 33(4):398-404. PubMed ID: 21529268
[TBL] [Abstract][Full Text] [Related]
48. The long pentraxin PTX3 in vascular pathology.
Mantovani A; Garlanda C; Bottazzi B; Peri G; Doni A; Martinez de la Torre Y; Latini R
Vascul Pharmacol; 2006 Nov; 45(5):326-30. PubMed ID: 17023219
[TBL] [Abstract][Full Text] [Related]
49. Correlation between the Banff 97 classification of renal allograft biopsies and clinical outcome.
Tanaka T; Kyo M; Kokado Y; Takahara S; Hatori M; Suzuki K; Hasumi M; Toki K; Ichimaru N; Yazawa K; Hanafusa T; Namba Y; Oka K; Moriyama T; Imai E; Okuyama A; Yamanaka H
Transpl Int; 2004 Feb; 17(2):59-64. PubMed ID: 14551678
[TBL] [Abstract][Full Text] [Related]
50. The long pentraxin PTX3 as a correlate of cancer-related inflammation and prognosis of malignancy in gliomas.
Locatelli M; Ferrero S; Martinelli Boneschi F; Boiocchi L; Zavanone M; Maria Gaini S; Bello L; Valentino S; Barbati E; Nebuloni M; Mantovani A; Garlanda C
J Neuroimmunol; 2013 Jul; 260(1-2):99-106. PubMed ID: 23664694
[TBL] [Abstract][Full Text] [Related]
51. Pentraxin-3 as a local inflammatory marker in chronic spontaneous urticaria.
Kasperska-Zajac A; Grzanka A; Misiolek M; Mazur B; Machura E
Cytokine; 2015 Dec; 76(2):566-568. PubMed ID: 25982553
[TBL] [Abstract][Full Text] [Related]
52. Pentraxin 3 and complement cascade activation in the failure of arteriovenous fistula.
Castellano G; Di Vittorio A; Dalfino G; Loverre A; Marrone D; Simone S; Schena FP; Pertosa G; Grandaliano G
Atherosclerosis; 2010 Mar; 209(1):241-7. PubMed ID: 19772962
[TBL] [Abstract][Full Text] [Related]
53. Pentraxin-3 and VEGF in POEMS syndrome: a 2-year longitudinal study.
Briani C; Dalla Torre C; Lessi F; Cavallaro T; Scarlato M; Ferrari S; Campagnolo M; Lucchetta M; Cabrini I; Morbin M; Lauria G; Adami F; Manfredi AA
J Neuroimmunol; 2014 Dec; 277(1-2):189-92. PubMed ID: 25447599
[TBL] [Abstract][Full Text] [Related]
54. Pentraxin-3 level at admission is a strong predictor of short-term mortality in a community-based hospital setting.
Bastrup-Birk S; Munthe-Fog L; Skjoedt MO; Ma YJ; Nielsen H; Køber L; Nielsen OW; Iversen K; Garred P
J Intern Med; 2015 May; 277(5):562-72. PubMed ID: 25143177
[TBL] [Abstract][Full Text] [Related]
55. Pentraxin 3 as a prognostic biomarker in patients with systemic inflammation or infection.
Liu S; Qu X; Liu F; Wang C
Mediators Inflamm; 2014; 2014():421429. PubMed ID: 25530683
[TBL] [Abstract][Full Text] [Related]
56. Pentraxins in nephrology: C-reactive protein, serum amyloid P and pentraxin-3.
Lech M; Rommele C; Anders HJ
Nephrol Dial Transplant; 2013 Apr; 28(4):803-11. PubMed ID: 23243042
[TBL] [Abstract][Full Text] [Related]
57. Differential expression of pentraxin 3 in fibroblasts from patients with major depression.
Shelton RC; Liang S; Liang P; Chakrabarti A; Manier DH; Sulser F
Neuropsychopharmacology; 2004 Jan; 29(1):126-32. PubMed ID: 14603263
[TBL] [Abstract][Full Text] [Related]
58. Low expression of pentraxin 3 and nuclear factor-like 2 implying a relatively longer overall survival time in gliomas.
Ke HH; Hueng DY; Tsai WC
Chin J Physiol; 2019; 62(1):35-43. PubMed ID: 30942197
[TBL] [Abstract][Full Text] [Related]
59. Increase in tissue and circulating pentraxin3 levels in patients with aortic valve stenosis.
Naito Y; Tsujino T; Akahori H; Ohyanagi M; Mitsuno M; Miyamoto Y; Hao H; Hirota S; Masuyama T
Am Heart J; 2010 Oct; 160(4):685-91. PubMed ID: 20934563
[TBL] [Abstract][Full Text] [Related]
60. Role of interleukin-6 and pentraxin 3 as an early marker in Peyronie's disease.
Atar A; Kural A; Yenice G; Comez I; Tugcu V
Kaohsiung J Med Sci; 2017 Apr; 33(4):195-200. PubMed ID: 28359407
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
